Non-Hodgkin Lymphoma Therapeutics Market 2024 – Market Size & Segments Analysis, Industry Trends, Manufacturers Analysis, Opportunities and Forecast 2030

The global market value of the non-Hodgkin lymphoma therapeutics market was valued at USD 9.4 billion in 2022, and a CAGR of 8.1% is expected during the forecast period. There is an increase in the number of promising pipeline drugs and an increasing number of cases of non-Hodgkin lymphoma, which is the most serious and life-threatening cancer.

Rising health awareness, expanding healthcare infrastructure, and a growing aging population are more susceptible to this disease, propelling market growth significantly. The introduction of novel therapies and ongoing research and development are driving the growth of the market. The increasing number of carcinoma patients worldwide is driving the growth of the market.

Impact of Covid-19

COVID-19 had a negative impact on the non-Hodgkin lymphoma treatment market due to delayed diagnosis, disruptions in the supply chain, and the diversion of resources towards COVID-19 management. However, the market also witnessed the increased adoption of telemedicine for consultation and a focus on home-based care solutions. Ongoing research and development in the field have found innovative treatment ways. Increasing cases of non-Hodgkin lymphoma are driving the growth of the market significantly.

Growth Drivers

The increasing number of lymphoma cases all around the world is driving growth in the market. Imbalance in lifestyle and an aging population all around the world are driving the growth of the market. Advancement in targeted therapies, immunotherapies, and personalized medicine is driving the growth of the market. Robust research and development activities and collaboration with pharmaceutical companies, especially in the North American region, are driving growth in the market. Improvements in early diagnosis and a growing awareness of available treatment options further fuel market expansion.

Lymphoma treatment varies according to the type, stage, and individual patient’s characteristics. Common approaches include chemotherapy, radiotherapy, immunotherapy, and stem cell transplantation. Regular monitoring and follow-up care are crucial to assessing treatment response and managing potential side effects. The increasing number of oncologists worldwide is driving the growth of the market significantly.

Segmentation

By Disease Type

·         Hodgkin Lymphoma

·         Non-Hodgkin Lymphoma

By Treatment Type

·         Immune Therapy

·         Targeted Therapy

·         Radio Therapy

·         Chemotherapy

By Route of Administration

·         Oral

·         Injectable

By Distribution Channel

·         Hospital Pharmacy

·         Online Pharmacy

·         Retail Pharmacy

Regional Outlook

·         Asia Pacific

·         North America

·         Latin America

·         Europe

·         Middle East and Africa

Non-Hodgkin Lymphoma Treatment Market by Disease Type Segmentation

On the basis of disease type, this market is segmented into Hodgkin lymphoma and non-Hodgkin lymphoma. Hodgkin lymphoma often involves a combination of chemotherapy, radiation therapy, and, in some cases, stem-cell transplantation. Non-Hodgkin lymphoma is diverse and includes chemotherapy, immunotherapy, targeted therapies, and, in certain situations, stem cell transplantation.

Non-Hodgkin Lymphoma Treatment Market by Distribution Channel Segmentation

On the basis of distribution channel, the non-Hodgkin lymphoma treatment market is segmented into retail pharmacies, online pharmacies, and hospital pharmacies. Hospital pharmacy is the leading segment in the region due to the increasing number of lymphoma patients all over the world. Increasing awareness among people about this life-threatening disease is growing the market worldwide. Retail pharmacies are another leading segment. The online mode is rapidly gaining popularity due to market trends.

Non-Hodgkin Lymphoma Treatment Market by Treatment Type Segmentation

On the basis of the treatment type, the market is segmented into immunotherapy, chemotherapy, targeted therapy, and stem cell therapy in some cases. Immunotherapy for Non-Hodgkin lymphoma involves stimulating the body’s immune system to recognize and attack cancer cells. Monoclonal antibodies, checkpoint inhibitors, and CAR-T cell therapy are prominent immunotherapies approaches, showing promising result in improving treatment outcome. Targeted therapy involves using drugs that specifically target certain molecules involved in the growth and survival of cancer cells. These drug aim to interfere with special pathway, that promotes cancer, minimizing damage to normal cells.

On the other hand Radiotherapy uses a high dose of radiation to damage the DNA of cancer cells, preventing them from multiplying. It is localized to a specific area, or used more broadly depending on the cancer type, and stage. In some cases the approaches are combined together like combining the precision of targeted therapy, with a broad reach of radio therapy to enhance effectiveness against the cancer cells. Increasing awareness among the people about the disease is growing the demand for these approaches. Increasing investment by the government on research and development activities is driving the growth in the market.

Regional Outlook

On the basis of the regions, the non-Hodgkin lymphoma treatment market is segmented into 5 parts: Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America is the leading segment and is expected to hold the top position in the market due to the increasing number of key players present in the market, the best healthcare infrastructure, and the large amount invested in research and development activities. The region is a hub for pharmaceutical and biotechnology companies, leading to the development of cutting-edge therapies.

Patients in North America often have better access to advanced therapies, including radiotherapy, chemotherapy, and targeted therapy. The high healthcare spending in North America supports the availability of state-of-the-art medical facilities, diagnostic technologies, and a comprehensive healthcare system that facilitates effective lymphoma treatment. The region actively participates in clinical trials, contributing to the development of new treatments. Access to a diverse patient population and collaborative research efforts contribute to advancements in non-Hodgkin lymphoma therapeutics. Greater awareness of cancer, including non-Hodgkin lymphoma, leads to early detection and intervention.

Screening programs and awareness campaigns contribute to a proactive approach to lymphoma management. Rising populations in emerging countries in the Asia-Pacific region, like India, China, and Indonesia, are driving growth in the market. The increasing geriatric population in Asia, the Pacific, and European countries is boosting market growth. Improving healthcare infrastructure and increasing the number of cancer institutes in the region are driving the growth of the market significantly. Increasing demand for immunotherapy, chemotherapy, and stem cell therapy in Asia, the Pacific, and European countries is driving the growth of the market significantly.

Key Players

·         Roche

·         Bristol Myers Squibb

·         Novartis

·         Pfizer

·         Gilead Sciences

·         Johnson and Johnson

·         Teva Pharmaceuticals Industry Ltd.

·         Ono Pharmaceuticals company Ltd.

·         Cipla INC

·         Abbott

·         Bausch Health Companies

·         Amneal Pharmaceuticals LLC

·         Hikma Pharmaceuticals PLC

·         Other Players